

FIG. 1




FIG. 2





FIG 3



## Fusion 1 and 2

1) Immunogen 12 (T = KLH, 12a), classical regimen

- 1) Immunogen **12** (T = KLH, **12a**), classical regimen
- 2)  $3.7 \times 10^8$  lymphocytes total
- 3) Fusion 1 = R0 myeloma, Fusion 2 = P3 myeloma, 47 plates each
- 4) Screened on MDMA-BSA 12 (T = BSA, **12b**) (in the presence and absence of free MDMA, MDEA, and pseudoephedrine), Amp-BSA 30, and MAMP-BSA 28

1) Immunogen 12 (T = KLH), deprotected, classical regimen

- (1) Immunogen 12 ( $\Gamma$  = KLH), deprotected, classical regimen
- (2)  $1.45 \times 10^6$  lymphocytes, 36 plates
- (3) 12 selected from 1,979 wells tested, same testing protocol as in Fusions 1 and 2.

Percent Cross-Reactivity

[illegible]

FIG. 5




FIG. 6




FIG. 7




FIG. 8


MDMA 2.1.1.1 Cross-Reactivity in Modified Roche OnLine Format

MDMA calibrators

	[MDMA] ng/mL	Rate
S1	0	15842
S2	250	12977
S3	500	10996
S4	1000	9434
S5	3000	8043

Span Data

S1-S2	2866	36.74%
S2-S3	1981	25.40%
S3-S4	1562	20.02%
S4-S5	1391	17.84%
Total	7799	



Drug	Amount spiked ng/mL	Instrument reading	% CR
d-MAMP	625	0	0
d-AMP	625	0	0
MDMA	625	714	114.2
MDEA	625	1864	298.2
BDB	5000	195	3.9
MBDB	5000	625	12.5
PPA	200000	0	0
Phent	200000	0	0
Phendim	200000	0	0
Tyramine	200000	0	0
l-eph	200000	0	0
d-pseudoeph	200000	0	0
l-AMP	200000	0	0
l-MAMP	200000	170	0.09